Navigation Links
Flu Viruses Gaining Resistance, Study Confirms
Date:12/7/2010

TUESDAY, Dec. 7 (HealthDay News) -- Certain influenza virus strains are developing increasing drug resistance and greater ability to spread, a new study warns.

American and Canadian researchers confirmed that resistance to the two approved classes of antiviral drugs can occur in several ways and said this dual resistance has been on the rise over the past three years.

The team analyzed 28 seasonal H1N1 influenza viruses that were present in five countries from 2008 to 2010 and were resistant to both M2 blockers (adamantanes) and neuraminidase inhibitors (NAIs), including oseltamivir and zanamivir.

The researchers found that additional antiviral resistance can rapidly develop in a previously single-resistant influenza virus through mutation, drug response, or gene exchange with another virus.

The study also found that the proportion of tested viruses with dual resistance increased from 00.6 percent in 2007-08 to 1.5 percent in 2008-09 and 28 percent in 2009-10.

The findings are published online Dec. 7 in advance of print publication Jan. 1 in the Journal of Infectious Diseases.

"Because only two classes of antiviral agents are approved, the detection of viruses with resistance to drugs in both classes is concerning," study author Dr. Larisa Gubareva, of the U.S. Centers for Disease Control and Prevention, said in a journal news release.

"If circulation of these viruses with dual resistance becomes more widespread among any of the predominant circulating influenza A viruses, treatment options will be extremely limited," she added. "New antiviral agents and strategies for antiviral therapy are likely to be necessary in the future."

Another study in the same issue of the journal examined an outbreak of oseltamivir-resistant pandemic H1N1 influenza in a hematology unit in a British hospital. The researchers concluded "that oseltamivir may not be the frontline drug of choice in hematology patients, and zanamivir may prove to be more beneficial."

In an editorial accompanying the two studies, experts said increased monitoring and creative prevention and treatment choices will be needed as unpredictable and antiviral-resistant influenza viruses continue to appear.

With only two classes of antiviral drugs approved for use in most countries, future research should focus on the effectiveness of zanamivir and combination antiviral therapy and the development of new types of antiviral drugs, wrote Dr. Frederick G. Hayden, of the University of Virginia School of Medicine, and Dr. Menno D. de Jong, of the University of Amsterdam in the Netherlands.

More information

The U.S. National Institute of Allergy and Infectious Diseases has more about influenza.

-- Robert Preidt

SOURCE: Journal of Infectious Diseases, news release, Dec. 7, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Potential new treatment for deadly nipah and hendra viruses identified by Weill Cornell researchers
2. Targeting hit-and-run cancer viruses
3. Researchers find function of proteins that can enhance the progression of viruses and cancer cells
4. To attack H1N1, other flu viruses, gold nanorods deliver potent payload
5. Mount Sinai discovers bone marrow plays critical role in enhancing immune response to viruses
6. Oncolytic viruses mediating anti-tumor immunity in human cancer patients
7. Mild-mannered metabolic helper rushes to fight invading viruses, researchers report
8. Oncos Therapeutics raises €4 million ($5.3 million) to develop oncolytic viruses into cancer treatment
9. UBC graduate student finds a start/stop switch for retroviruses
10. New Study: Improved Immune System with Gene-Eden, a Natural Antiviral Supplement that Targets Chronic Viruses
11. Gaining Weight Raises Risk of Heart Disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Flu Viruses Gaining Resistance, Study Confirms
(Date:8/22/2017)... ... August 22, 2017 , ... Five Star Glass is new to the Texas market, but ... of auto glass for most makes and models, in Grand Prairie, TX, located in the ... They have been a family owned business for the past 40 years with 32 convenient ...
(Date:8/22/2017)... ... , ... “Glimpses Of Light”: is a unique and thought inspiring guide ... creation of published author, J.M. Shepherd, a writer, teacher, traveler, and metaphysician, the author ... , Shepherd shares, “Love is one of the least understood and yet most sought-after ...
(Date:8/21/2017)... MO (PRWEB) , ... August 22, 2017 , ... PracticeMatch, ... fairs to help healthcare employers connect with physicians and advanced practitioners like nurse ... virtual career fairs in August through November of this year. The online career ...
(Date:8/21/2017)... ... 2017 , ... SportsEngine, Inc. , a division of ... of North Country Region Volleyball and will power registration, scheduling, and competition results ... sport management software to their member clubs. , SportsEngine provides financial ...
(Date:8/21/2017)... ... , ... PIXACORE , an independent full-service agency with a decade of ... the year by MM&M. , This is the first time PIXACORE has made the ... agency. PIXACORE’s newfound recognition reflects its steady trajectory of growth and recent strategic ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... 2017 Three Tru-D SmartUVC robots have arrived at ... . Tru-D, short for "Total Room Ultraviolet Disinfection," is a 5-foot-5 ... environmental services (ES) professional cleans the area with traditional cleaning protocols. ... Tru-D fights germs at ... "Although the BAACH has a very low ...
(Date:7/27/2017)... 27, 2017  Zimmer Biomet Holdings, Inc. (NYSE and ... June 30, 2017.  The Company reported second quarter net ... the prior year period, and an increase of 2.1% ... points of contribution from the LDR Holding Corporation acquisition, ... quarter of 2016, or 0.3% on a constant currency ...
(Date:7/26/2017)... 26, 2017 Sancilio Pharmaceuticals Company, Inc. (SPCI) ... trial evaluating Altemia TM , an oral therapy for ... Cell Disease (SCD). The SCOT Trial, is a double-blind, ... safety of Altemia TM in pediatric patients aged ... IND 125274. "The ...
Breaking Medicine Technology: